New study tracks how well ropeginterferon eases symptoms in polycythemia vera patients
NCT ID NCT06743035
First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 21 times
Summary
This study follows about 200 adults with polycythemia vera (a blood disorder) who do not have an enlarged spleen and are starting treatment with ropeginterferon alfa-2b. Researchers will track symptoms, blood cell counts, and side effects over 36 months in real-world clinics. The goal is to see how well the drug controls the disease and improves daily life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde
RECRUITINGHanover, Lower Saxony, 30161, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.